These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30322469)

  • 1. [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
    Seguí Díaz M
    Semergen; 2018 Jun; 44 Suppl 1():18-25. PubMed ID: 30322469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations of the main clinical practice guidelines].
    Miravet I Jiménez S
    Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
    Carramiñana Barrera FC
    Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Incretin mimetic drugs: therapeutic positioning].
    López Simarro F
    Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia.
    Boucaud-Maitre D
    BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596
    [No Abstract]   [Full Text] [Related]  

  • 10. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C; Bollaerts K
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies.
    Molina-Vega M; Muñoz-Garach A; Fernández-García JC; Tinahones FJ
    Expert Opin Drug Saf; 2018 Aug; 17(8):815-824. PubMed ID: 29975558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
    Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
    Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.